Amylyx avexitide cuts serious low blood sugar events by 55% in Phase 3 trial for post bariatric hypoglycemia

Amylyx Pharmaceuticals reported that its experimental drug avexitide significantly reduced the frequency of serious low blood sugar episodes in a Phase 3 study of patients with post‑bariatric hypoglycemia. Participants receiving the drug experienced a 55% drop in such events compared with those on placebo, exceeding the trial’s predefined goal of a 35% improvement.

Post‑bariatric hypoglycemia is a condition that can cause sudden, dangerous drops in blood glucose after weight‑loss surgery, sometimes leading to loss of consciousness or seizures. The reduction observed in the study suggests a meaningful clinical benefit for a patient group that currently has no approved therapy.

The positive readout positions avexitide as a potential first‑in‑class treatment, and Amylyx said the data pave the way for regulatory submission. If approved, the drug could address an unmet need and attract interest from investors focused on metabolic and obesity‑related therapies.